Клиническое значение тестирования на вирус папилломы человека в скрининге цервикальной интраэпителиальной неоплазии
Диссертация
Алгоритмы применения ВПЧ-теста на первом этапе скрининга только проходят апробацию. Обсуждается его использование для сортировки неясных цитологических мазков и постлечебного мониторинга плоскоклеточных интраэпителиальных поражений высокой степени тяжести с целью обнаружения остаточных поражений. Однако важно заметить, что обсуждаемые исследования все еще имеют методологические недостатки, что… Читать ещё >
Список литературы
- Гинекология: национальное руководство / под ред. В. И. Кулакова, И. Б. Манухина, Г. М. Савельевой. М.: ГЭОТАР-Медиа, 2007. — С.744.
- Злокачественные новообразования в России в 2007 году (заболеваемость и смертность) под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой // М.: ФГУ «МНИОИ им. П. А. Герцена Росмедтехнологий», 2009. С. 5130.
- Киселев В.И., Киселев О. И. Этиологическая роль вируса папилломы человека в развитии рака шейки матки: генетические и патогенетические механизмы //Цитокины и воспаление. 2003. — Т. 2. — № 4.- С. 31−38.
- Киселев Л.Л., Абелев Г. И., Киселев Ф. Л. Как Сирано де Бержерак, он мог гордиться белым султаном своего боевого шлема: К 100-летию со дня рождения Л. А. Зильбера // Природа. 1994. — N 6. — С. 66−84.
- Кузнецова Ю.Н. Латентная папилломавирусная инфекция урогенитально-го тракта женщин, обусловленная ВИЧ 16-го и 18-го типов. Варианты течения, тактика ведения: автореф. дис.. канд. мед. наук. Екатеринбург, 2003.-17 с.
- Левшин В.Н., Заридзе Д. Г. Табак и злокачественные образования // Вопросы онкологии. 2003. — Т. 49. — № 4. — С. 394- 397.
- Маныкин A.A., Завалишина Л. Э., Франк Г. А., с соавт. Использование методов ПЦР и гибридизации in situ для типирования папилломавирусов в биоптатах гортани человека // Новости клинической цитологии России. -2001. -Т.5. -№ 1−2. С. 91.
- Минкина Г. Н., Манухин И. Б., Франк Г. А. Предрак шейки матки. М.: Аэрограф-медиа, 2001. — С. 112−117.
- Минкина О.В. Рациональная диагностика генитальной папилломавирусной инфекции: дис. канд. мед. наук. М, 2004. — С.123.
- Мынбаев O.A., Елисеева М. Ю., Дж. Доорбар, Манухин КБ. Эпидемиология, молекулярная биология и принципы иммунотерапии папиллома-вирусной инфекции // Вопросы гинекологии, акушерства и перинатоло-гии. 2009. — Т.8. — № 3. — С.69−79.
- Олийниченко П.И., Собко Н. П. Цитологический скрининг рака шейки матки в Киеве и вопросы его совершенствования // Лаб. диагностика. -2000.-№ 2.-С. 48- 52.
- Подистов Ю.И. Роль вируса папилломы в развитии предрака и рака шейки матки // Клиническая лабораторная диагностика. 2003. — № 5. -С. 44−50.
- Подистов Ю.И., Лактионов К. П., Петровичев H.H. Современные диагностические возможности в определении предрака и рака шейки матки // Клиническая лабораторная диагностика. 2003. — № 3. — С. 15−24.
- Полимеразная цепная реакция и ее применение для диагностики в дерматовенерологии: учеб. пособие / под ред. A.A. Воробьева. М.: МИА, 2004. — 72 с.
- Профилактика рака шейки матки: руководство для врачей. М.: МЕД-пресс-информ, 2007. — С.48.
- Роговская С.И. Папилломавирусная инфекция нижних отделов гениталий: клиника, диагностика, лечение: автореф. дис.. докт. мед. наук. -М., 2003.-40 с.
- Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. М.: ГЭОТАР-Медиа, 2008. — 2-е изд. — 192 с.
- Сирйонен К. Репродуктивное здоровье, в 2-х томах, т.2. Редкие инфекции / Пер. с англ. под ред. Л. Кейта, Г. Бергера, Д. Эдельмана. М.: 1998. -С. 169−189.
- Туманян А.Г., Шахнес И. Е. Лечение вульгарных и подошвенных бородавок однократным обкалыванием пирогеналом // Российский журнал кожных и венерических болезней. -М., 1999. № 1. — С. 49−50.
- Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология: основы доказательной медицины. М.: МедиаСфера, 1998. — 352 с.
- Фролова И.И. Диагностика цервикальных интраэпителиальных неопла-зий: реальность и перспективы // Вопросы гинекологии, акушерства и пе-ринатологии. 2003. — Т. 2. — № 4. — С. 80- 83.
- Чепурная Ю.Ю. Роль жидкостной цитологии в диагностике заболеваний шейки матки: дис.. канд. мед. наук. -М., 2004. 184 с.
- Черезов А.Е. Общая теория рака: тканевой подход. М.: Изд-во МГУ, 1997.-252 с.
- Шабалова И.П., Касоян К. Т. Цитологический атлас. Цитологическая диагностика заболеваний шейки матки. — М., 2006. С. 15.
- Шабалова И.П. Цитологический атлас. Критерии диагностики заболеваний шейки матки. М., 2001 .-113с.
- Шипицына Е.В., Бабкина К. А., Оржесковская Е. А., Савичева A.M. Па-пилломавирусная инфекция: факторы риска цервикальной неопластической прогрессии // Журн. акушерства и женских болезней. 2004. — Т.Ш.- № 3. С.34−41.
- Abulafia О., Pezzullo J.C., Sherer D.M. Performance of ThiiiPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey // J. Gynecologycal Oncology. 2003. — Vol. 90.- № 1. P. 137- 144.
- Andy C., Turner L.F., Neher J.O. Is the TliinPrep better than conventional Pap smear at detecting cervical cancer? // J. Fam. Pract. 2004. — Vol. 53. — № 4. -P. 313−315.
- Arbyn M., Buntinx F., Van Ranst M., et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia // J. Natl. Cancer. Inst. 2004. — № 96. — P. 280−293.
- Arbyn M., Sasieni P., Meijer C., et al. Clinical applications of HPV testing: a summary of meta-analyses // Vaccine. 2006. — № 24 (suppl.3). — P. 78−89.
- Arbyn M., Anttila A., Jordan J., et al. European guidelines for quality assurance in cervical cancer screening. Luxembourg: European Commission, Office for Official Publication of the European Communities, 2007.
- Arbyn M., Bergeron C., Klinkhamer P. et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis // Obstet. Gynecol. 2008. — Vol. 111. — № 1. — P. 167−177.
- Arbyn M., Martin-Hirsch P., Buntinx F., et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positiv-ity rate // J. Cell. Mol. Med. 2009. — Vol. 13. — № 4. — P. 648−659.
- Autillo-Teuati A., Joannes M., d’Ercole C., et al. HPV-Typing by in Situ Hybridization on Cervical Cytologic Smears with ASCUS // J. Acta Cytologica. -1998. Vol. 42. — № 3. — p. 631- 639.
- Baker J.J. Conventional and liquid-based cervicovaginal cytology: a comparison study with clinical and histologic follow-up // Diagn. Cytopathol. 2002. -Vol. 27.-№ 3.-P. 185−188.
- Baldauf J.J., Dreyfus M., Ritter J. et al. Screening histories of incidence cases of cervical cancer and high grade SIL. A comparison // J. Acta Cytologica. -1997. Vol. 41. -№ 5. -P. 1431- 1438.
- Baldwin P., Laskey R., Coleman N.N. Translation approaches to improving cervical screening // J. Cancer. 2003. — Vol. 3. — P. 217.
- Ball C., Madden J.E. Update cervical cancer screening // Postgraduate Medicine. -2003.-Vol. 113. -№ 2.-P. 59−70.
- Barrasso R. Colposcopic diagnosis of HPV cervical lesions // IARC Sci Publ. -1992.-Vol. 119.- P. 67−74.
- Bekkers R., Meijer C., Massuger L., et al. Effects of HPV detection in population-based screening programmes for cervical cancer- a Dutch moment // Gynecol. Oncol. 2006. — Vol.100. — № 3. — P. 451−454.
- Bergeron C., Bishop J., Lemarie A., et al. Accuracy of thin-layer cytology in patients undergoing cervical cone biopsy // Acta Cytol. 2001. — Vol. 45. — P. 519−524.
- Birner P., Schindl M., Stani J., et al. Hybrid capture based human papillomavirus typing in cervical screening compared to cytology and histology // WienKlin. Wochenschr. -2000. Vol. 17. -№ 11. -P.761−766.
- Biscotti C.V., O’Brien D.L., Gero M.A., et al. Thin-layer Pap test vs. conventional Pap smear. Analysis of 400 split samples // J. Reprod. Med. 2002. -Vol. 47. — P. 9−13.
- Bollmann R., Mehes G., Torka R., et al. Human papillomavirus typing and DNA ploidy determination of squamous intraepithelial lesions in liquid-based cytologic samples // Cancer (Cancer Cytopathology). 2003. — Vol. 99. — № 1. — P. 57−62.
- Bosch F.X., de Sanjose S. Human papillomavirus in cervical cancer // J. Current Oncology Reports. 2002. — Vol. 4. — № 2. — P. 175- 183.
- Bosch F.X., Lorincz A., Munoz N, Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer // J. Clin. Pathol. -2002. Vol. 55. — P. 244−265.
- Bosch F.X. Epidemiology of human papillomavirus infection: new options for cervical cancer prevention // Salud. Publica Mex. 2003. — V.45., suppl. -S.326−339.
- Bosch F.X., de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer // Dis. Markers. 2007. — Vol. 23. — № 4. — P. 213−227.
- Boyle P., Autier P., Bartelink H. et al. European code against cancer and scientific justification: third version (2003) // Ann. Oncol. 2003. — Vol. 14. — P. 973−1005.
- Brink A.A., Snijders P.J., Meijer C.J., et al. HPV testing in cervical screening // Best Pract. Res. Clin. Obstet. Gynaecol. 2006. — Vol. 20. — № 2. — P. 253 266.
- Bulkmans N.W., Rozendaal L., Voorhorst F.J., et al. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening //Br. J. Cancer. 2005. — Vol. 92. — P. 1800−1802.
- Buntinx F., Arbyn M. Conventional cervical smears were better than monolayer cytology or human papillomavirus testing for detection cervical cancer // J. Evidence Based Medicine. 2003. — Vol. 8. — P. 187.
- Burchell A.N., Tellier P.P., Hanley J., et al. Influence of Partner’s Infection Status on Prevalent Human Papillomavirus Among Persons With a New Sex Partner // Sex. Transm. Dis. 2010. — Vol. 37. — № 1. — P. 34−40.
- Cao Y., Zhao J., Lei Z., et al. Local accumulation of FOXP3+ regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminate // J. Immunol. 2008. — Vol. 180. — № 11. — P.7681−7686.
- Carol B., Joan E.M. Update on cervical cancer screening. Current diagnostic and evidence-based management protocols // J. Postgraduate Medicine. 2003. -Vol. 113. -№ 2. — P.59−70.
- Carvalho M.O., Almeida R.W., Leite F.M., et al. Detection of human papillomavirus DNA by the hybrid capture assay // Brazilian Journal of Infectious Diseases. -2003. Vol. 2. -№ 5. — P. 121−125.
- Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer//Gynecol. Oncol. -2008. Vol.110 (3 Suppl 2):S4−7.
- Castellsague X., Bosch F.X., Munoz N. Environmental co-factors in HPV carcinogenesis // Virus. Res. 2002. — Vol. 89. — P. 191−199.
- Castellsague X., Diaz M., de Sanjose S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications forscreening and prevention // O. Natl. Cancer. Inst. 2006. — Vol. 98. — № 5. — P. 303−315.
- Castle P.E., Rodriguez A.C., Porras C., et al. A comparison of cervical and vaginal human papillomavirus // Sex. Transm. Dis. 2007. — Vol. 34. — № 11. -P. 849−855.
- Castle P.E., Rodriguez A.C., Burk R.D., et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study // BMJ. 2009. — Vol. 28- 339: b2569. doi:10.1136/bmj.b2569.
- Cheung A.N., Szeto E.F., Leung B.S., et al. Liquid-based cytology and conventional smears: a comparison study in Asian screening population // Cancer. -2003. Vol. 99. — P. 331 -335.
- Chhieng D.C., Talley L.I., Roberson J. Interobserver variability: comparison between liquid-based and conventional preparations in gynecologic cytology // J. Cancer. 2002. — Vol. 96. — № 2. — P. 67−73.
- Clavel C., Cucherousset J., Lorenzato M., et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions // Br. J. Cancer. 2004. — Vol. 90. — P. 18 031 808.
- Clifford G.M., Smith J.S., Aguado T., Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis // Br. J. Cancer. 2003. — Vol. 89. — P. 101−105.
- Clifford G.M., Smith J.S., Plummer M., et al. Human papillomavirus type in invasive cervical cancer worldwide: a meta-analysis // Br. J. Cancer. 2003. -Vol. 88.-№ 1.-P. 63−73.
- Clifford G, Franceschi S. Members of the human papillomavirus type 18, family (alpha-7 species) share a common association with adenocarcinoma of the cervix // Int. J. Cancer. 2008. — Vol. 122. — № 7. — P. 1684−1685.
- Colgan T.J., Machlin M., Collerchio M., et al. Results of the implementation of liquid-based cytology — SurePath in the Ontario Screening Program // Cancer. 2004. — Vol. 102. — P. 362−367.
- Cogliano V., Baan R., Straif K., et al. WHO International Agency for Research on Cancer: Carcinogenicity of human papillomaviruses // Lancet. Oncol. 2005. — Vol. 6. — № 4. — P. 204.
- Cox J.T. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings // JAMA. -1999. Vol. 281. — № 1. — P. 1645−1647.
- Cuschieri K.S., Cubie H.A., Whitley M.W., et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population // Clin. Pathol. 2004. — Vol.57. — P. 68−72.
- Cuzick J., Szarewski A., Cubie H., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study // Lancet. 2003. — Vol. 362. — P. 1871−1876.
- Cuzick J., Mayrand M.H., Ronco G., et al. Chapter 10: new dimensions in cervical cancer screening// Vaccine. 2006. — 24(suppl 3): S90-S97.
- Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening // Int. J. Cancer. -2006. Vol. 119. -P. 1095−1101.
- Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of Human Papillomavirus-based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries // Vaccine. 2008. — 26(Suppl 10): K29−41.
- Daling J.R., Madeleine M.M., Johnson L.G., et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer // Cancer. 2004. -Vol. 101.-P. 270−80.
- Dalstein V., Reithmuller D., Pretet J., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study // Int. O. Cancer. 2003. — Vol. 106. — № 3. — P. 396 403.
- Dalstein V., Bory J., Graesslin O., et al. Human papillomavirus testing for primary cervical cancer screening. Monsonego J (ed): Emerging issues on HPV infections: from science to practice. Basel, Karger. — 2006. — P. 103−119.
- Daron G.F., Nicole L.H., Mark S.L., John H.C., Macfee M.S. The Efficacy of Liquid-Based Cervical Cytology Using Direct-to-Vial Sample Collection // Journal of Family Practice. —2000. — Vol. 49. № 11. — P. 324- 327.
- Davey D.D., Armenti C.A. HPV primary screening for cervical cancer: more pain than protection // J. Diagnostic. Cytopathology. 2000. — Vol. 22. — P. 333−335.
- Davey D.D. Cervical cytology classification and the Bethesda System // Cancer J. 2003. — Vol. 9. — № 5. — P. 327−334.
- Depuydt C.E., Vereecken A.J., Salembier G.M., et al. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women // Br. J. Cancer. 2003. — Vol. 88. — № 4. — P. 560−566.
- Diane M. Harper. Why Am I Scared of HPV? // CA Cancer J. Clin. 2004. -Vol. 54.-P. 245−247.
- Do Horto dos Santos Oliveira L., Rodrigues E.V., de Salles Lopes A.P. HPV 16 detection in cervical lesions, physical state of viral DNA and changes in p53 gene // San Paulo Med. J. 2003. — Vol. 121. — № 2. — P. 67−71.
- Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer // Clin. Sci (Lond). 2006. — Vol. 110. — № 5. — P. 525−41.
- Dupree W.B., Suprun H.Z., Beckwith D.G., et al. The promise and risk of new technology. The Lehing Valley Hospitals experience with liquid-based cytology // Cancer. 1998. — № 84. — P. 202−207.
- Elfgren K., Kalantari M., Moberger B., et al. A population based five-year follow-up study of cervical human papillomavirus infection // Am. J. Obstet. Gynecol. -2000. Vol. 183. -P. 561−567.
- Evander M., Edlund K., Gustafsson A., et al. Human papillomavirus infection is transient in young women: a populationbase cohort study // J. Infect. Dis. -1995.-Vol. 171. -P.1026−1030.
- Ferlay J., et al. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide // IARC CancerBase- Lyon, 2004.
- Franco E., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection // CNAJ. 2001. -Vol. 164.-P. 1017−1025.
- Franco E.L., Cuzick J., Hildesheim A., de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination // Vaccine. 2006. -24:Supp. 3. S171-S177.
- Frazer I.H. Interaction of human papillomaviruses with the host immune system: A well evolved relationship // Virology. 2009. — Vol. 384. — № 2. — P. 410−414.
- Fremont-Smith M., Marino J., Griffin B., Spencer L., Bolick D. Comparison on the SurePath liquid-based Papanicolau smear with the conventional Papanicolaou smear in a multisite direct-to-vial study // Cancer. 2004. — Vol. 102. -P. 269−279.
- Ghaemmaghami F., Behtash N., Modares Gilani M., et al. Visual inspection with acetic acid as a feasible screening test for cervical neoplasia in Iran // Int. J. Gynecol. Cancer. 2004. — Vol. 14. — № 3. — P. 465−469.
- Girianelli V.R., Azevedo E., Silva G., Thuler L.C. Factors associated with the risk of progression to precursor lesions or cervical cancer in women with negative cytologic findings // Int. J. Gynaecol. Obstet. 2009. — Vol. 107. — № 3. -P.228−231.
- GLOBOCAN database. http://www-dep.iarc.fr / last access 25.01.2007.
- Gonzalez P., Hildesheim A., Rodriguez A., et al. Appearance of new HPV infection among women older than 45-years // The 25th international papillomavirus conference. -Malmo, Sweden, 2009. -P-06.07.
- Grace A., McBrearty P., Troost S., et al. Comparative study: conventional cervical and ThinPrep Pap tests in a routine clinical setting // Cytopathology. -2002. Vol. 13. — № 4. — P. 200−205.
- Gravitt P.E., Coutlee F., Iftner T., et al. New Technologies in Cervical Cancer Screening // Vaccine.-2008.-26 Suppl. 10: K42−52.
- Grce M., Davies P. Human papillomavirus testing for primary cervical cancer screening // Expert. Rev. Mol. Diagn. 2008. — Vol. 8. — № 5. — P. 599−605.
- Harvey McConnell. Conventional Cervical Smear Test Better Than Newer Monolayer Cytology I I British. Medical. Journal. 2003. — Vol. 326. — № 12. -P. 733- 736.
- Health Canada: Cervical cancer screening in Canada: 1998 Surveillance. Report. 2002.
- Hellberg D., Stendahl U. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer // Anticancer Res. 2005. — Vol. 25. — № 4. — P. 3041−3046.
- Herbert A., Bergeron C., Wiener H., et al. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology// Cytopathology. 2007. — Vol. 18. — P. 213−219.
- Herbst A.L., Pickett K.E., Folien M., Noller K.L. The management of ASCUS cervical cytologic abnormalities and HPV testing: a cautionary note // Journal of Obstetric, and Gynecology. 2001. — Vol. 98. — P. 849- 851.
- Howard K., Salkeld G., McCaffery K., Irwig L. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? // Health Econ. 2008. — Vol. 17. -№ 5.-P. 593−605.
- Hoyer H., Scheungraber C., Kuehne-Heid R., et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting // Int. J. Cancer. 2005. — Vol. 116.-P. 136−143.
- Hubbard R.A. Human papillomavirus testing methods // J. Arch. Pathology in Laboratory Medicine. 2003. — Vol. 27. — № 8. — P. 940−945.
- Jayasinghe Y., Sasongko V., Moore E., et al. Risk factors for early onset cer• TIT #vical carcinoma and high-grade dysplasia // Abstract. 25 International Papillomavirus conference. Malmo, Sweden, 2009. — P-03.13.
- Jones B. A, Davey D.D. Quality management in gynecologic cytology using interlaboratory comparison // Arch. Pathol. Lab. Med. 2000. — Vol. 124. — P. 665−672.
- Josefsson A., Magnusson P., Ylitalo N. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study // Lancet. 2000. — Vol. 355. — № 9222. — P. 2189−2193.
- Kamb M.L. Cervical Cancer Screening of Women attending STD clinics // Clinical Infectious Diseases. 1995. — Vol.20. — № 1 -P.98−103.
- Kitchener H.C., Almonte M., Wheeler P., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial // Br. J. Cancer. -2006.-Vol. 95.-P. 56−61.
- Kitchener H.C., Castle P.E., Cox J.T. Chapter 7: achievements and limitations of cervical cytology screening // Vaccine. 2006. — Vol. 24(suppl.3): S63-S70.
- Kitchener H.C., Almonte M., Thomson C. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial // Lancet Oncol. 2009. — Vol. 10. — № 7. — P. 672−682.
- Kjaer S.K., Tran T.N., Sparen P., et al. The burden of genital warts: a study of hearly 70,000 women from the general female population in the 4 Nordic countries // J. Infect. Dis. 2007. — Vol. 196. — № 10. — P. 1447−1454.
- Kotaniemi-Talonen L., Nieminen P., Anttila A., Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomized setting//Br. J. Cancer. 2005. — Vol. 93. — P. 862−867.
- Kotaniemi-Talonen L., Anttila A., Malila N., et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3 // Eur. J. Cancer. 2008. — Vol. 44. — № 4. — P. 565 571.
- Lawson M.A. Human papillomavirus infection in adolescent and young women // Mo Med. 2008. — Vol. 105. — № 1. — P. 42−46.
- Leinonen M., Nieminen P., Kotaniemi-Talonen L.J., et al. Age-specific evaluation of primaiy human papillomavirus screening vs conventional cytology in a randomized setting // Natl. Cancer Inst. 2009. — Vol. 101. — № 23. -P.1612−1623.
- Lorincz A.T., Richart R.M. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs // Arch. Pathol. Lab. Med. 2003. -Vol. 127. — № 8. — P. 959−68. Review.
- Lowy D.R., Solomon D., HUdesheim A., Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer // Cancer. -2008. Vol. 113 (7 Suppl.). -P. 1980−1993.
- Maalke C.S., Anneke Dijkman, Mohammed Farid Aziz, et al. Prevalence of single and multiple HPV types in cervical Carcinomas in Jakarta, Indonesia // J. Gynecologic Oncology. 2004. — Vol. 93. — P. 49−53.
- Malle D., Pateinakis P., Chakka E., Destouni C. Experience with a thin-layer, liquid-based cervical cytologic screening method // J. Acta Cytologyca. 2003. — Vol. 47. — № 2. — P. 129−134.
- Mark W. Human papillomavirus infection // Journal of the American academy of Dermatology. 1990. — Vol. 22. — № 4. — P. 547−566.
- Martin-Hirsch P.L., Koliopoulos G., Paraskevaidis E. Is it now time to evaluate the true accuracy of cervical cytology screening? // Eur. J. Gynaecol. Oncol. -2002. Vol. 23. — № 4. — P. 363−365.
- Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. For the Canadian Cervical Cancer Screening Trial Study Group // N. Engl. J. Med. 2007. -Vol. 357.-P. 1579−1588.
- McFarlane-Anderson N., Bazuaye P.E., Jackson M.D., et al. Cervical dysplasia and cancer and the use hormonal contraceptives in Jamaican women // BMC Women’s Health. 2008. — Vol. 8. — P.9.
- Meijer C.J., Snijders P.J., Castle P.E. Clinical utility of HPV genotyping // Gynecol. Oncol. 2006. — Vol. 103. — № 1. — P. 12−17.
- Meijer C. HPV testing in primary screening. International Multidisciplinary Conference: Joining Forces for Cancer Prevention. 2008.
- Meijer CJ., Berkhof J., Castle P.E., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older // Int. J. Cancer. 2009. — Vol. 124. — № 3. — P. 516−520.
- Milde-Langosch K., Riethdorf S., Loning T. Association of human papillomavirus infection with carcinoma of the cervix uteri its precursor lesions: theoretical and practical implications // Virchows Arch. 2000. — Vol. 437. — P. 227−233.
- Moberg M., Gustavsson I., Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ // Int. J. Cancer. 2004. — Vol. 112. — № 5. — P. 854−859.
- Moberg M., Gustavsson I., Wilander E., et al. High viral load of human papillomavirus predict risk of invasive cervical carcinoma // Br. J. Cancer. 2005. -Vol. 92. -P. 891−894.
- Monsonego J. Colposcopy: the value of HPV testing in clinical practice // Gynecol. Obstet. Fertil. 2004. — Vol. 32. — № 1. — P. 62−74.
- Monsonego J., Bosch F., Coursaget P., et al. Cervical Cancer Control Priorities and new directions // Int. J. Cancer. 2004. — Vol. 108. — P. 329−333.
- Munoz N, Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer // New England Journal of Medicine. 2003. — Vol. 348. — № 6. — P. 518−527.
- Naucler P., Ryd W., Tornberg S., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer // N. Engl. J. Med. 2007. — Vol. 357. -№ 16.-P. 1589−1597.
- Naucler P., Ryd W., Tornberg S., et al. Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening // JNCI J. Natl. Cancer Inst. 2009. — Vol. 101. — P. 88−99.
- Negri G., Rigo B., Vittadello F., et al. Abnormal cervicovaginal cytology with negative human papillomavirus testing // Cancer. 2007. — Vol. 111. — № 5. -P. 280−284.
- Papanicolaou G.N., Traut H.F. The diagnostic value of vaginal smears in carcinoma of the uterus // Am. J. Obstet. Gynecol. 1941. — Vol. 42. — P. 193 206.
- Paraskevaidis E., Arbyn Mv Sotiriadis et al. The role of DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature // Cancer treat. Rev. 2004. — Vol. 30. — P. 205−211.
- Petry K.U., Menton S., Menton M., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients // Br. J. Cancer. 2003. — Vol. 88. — P. 1570−1577.
- Ponten J., Adami H-O., Bergstrom R., et al. Strategies for global control of cervical cancer // International Journal of Cancer. 1995. — Vol. 60. — P. 1−26.
- Powell J.L. Biographic sketch: Powell’s Pearls: Hans Peter Hinselmann, MD (1884−1959) //Obstet. Gynecol. Surv. -2004. Vol. 59. — P. 693−695.
- Reagan J.W., Seidemand I.L., Saracusa Y. The cellular morphology of carcinoma in situ and dysplasia or typical hyperplasia of the uterine cervix // Cancer. 1953. — Vol. 6. — P. 224−235.
- Reid R., Scalzi P. Genital warts and cervical cancer. VH. An improved colpo-scopic index for differentiating benign papillomaviral infections from highgrade cervical intraepithelial neoplasia // Am. J. Obstet. Gynecol. 1985. -Vol. 153.-P. 611−618.
- Richart R., Meijer C., Cuzick J., Kjaer S. Symposium: Human Papillomavirus and cervical cancer screening // J. Obstetrics and Gynecology. 2000. — Vol.11.-P. 71−101.
- Richart R.M., Robles S., Wright T.C., Sankaranarayanan R. Cervical cancer screening strategies for developing countries // Am. J. Obstet. Gynecol. 2001. -Vol. 1.-P. 71−79- 100−117.
- Rigoni-Stern D. 'Fatti statistici alle mallattie cancerose che servirono di base alle poche cose dal dott' Italian. // F. Prog. Patol. Terap. 1842. — Vol. 2. — P. 499−517.
- Rinas AS. The gynecological PAP test // Clin. Lab. Science. 1999. — Vol.12.-P. 239−245.
- Rodriguez A.C., Schiffman M., Herrero R., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections // J. Natl. Cancer Inst. 2008. — Vol. 100. — № 7. — P. 513−517.
- Ronco G., Cuzick J., Segnan N., et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology // Eur. O. Cancer. 2007. — Vol. 43. — № 3. — P. 476−480.
- Runowicz C.D. Molecular screening for cervical cancer — time to give up Pap tests? // N. Engl. J. Med. 2007. — Vol. 357. — P. 1650−1653.
- Sanlcaranarayanan R., Black R.J., Parkin D.M. Cancer survival in developing countries // IARC. Scientific publication. — Lyon, 1998. — № 145.
- Sankaranarayanan R., Chatterji R., Shastri S.S., et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India // Int. J. Cancer. 2004. — Vol. 112. — P. 341−347.
- Sankaranarayanan R., Esmy P.O., Rajkumar R. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial // Lancet. 2007. — Vol. 370. — № 9585. — P. 398−406.
- Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer // Clinical Journal of Cancer. 2002. — Vol. 52. — № 6. -P. 342−362.
- Schiffinan M.N., Liaw K.L., Herrero R., et al. Epidemiologic support for a simplified view of cervical carcinogenesis // Genital infection and Neoplasia. -1998.-Vol. 1. -№ 6. — P. 2−6.
- Schiffman M., Herrero R., Desalle R., Hildesheim, et al. The carcinogenicity of human papillomavirus types reflects viral evolution // Virology. 2005. -Vol. 337. — P.76−84.
- Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer // Lancet 2007,370(9590):890−907.
- Schiffinan M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing // Cancer. 2007. — Vol. 111. — № 3. — P. 145−153.
- Schiffinan M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline // Infect. Agent Cancer. 2009. — Vol. 4. — P. 8. Review.
- Schlecht N.F., Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia // J. Am. Med. Assoc. 2001. — Vol. 286. — P. 3106−3114.
- Scully R., Bonfiglio T. WHO classification of tumors of female genital tract // New York. Springer — Verlag. — 1994.
- Sherman M. Future direction in cervical pathology // JNCI Monographs № 31. Oxford University Press 2003. P. 80−88.
- Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis // O. Natl. Cancer Inst. 2003. — Vol. 95. — P. 46−52.
- Simen-Kapeu A., Luostarinen T., Jellum E., et al. Smoking is an independent1. TTIrisk for invasive cervical cancer. London, United Kingdom // Abstract. 25 International Papillomavirus Conference. Malmo, Sweden, 2009. — P-03.20.
- Singer A., Coppleson M., Canfell K., et al. A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: A multicenter evaluation //Int. O. Gynecol. Cancer. -2003. -№ 13. -P. 804−811.
- Smith R.A., Cokkinides V., Eyre H. American Cancer Society Guidelines for the early detection of cancer // CA Cancer J. Clinic. 2004. — Vol. 54. — № 1. -P. 41−52.
- Snijders P.J., van den Brule A.J., Meijer C.J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity // J. Pathol. 2003. — Vol. 201. — № 1. — P. 1−6.
- Snijders J., Meijer C. The Value of Viral Load in HPV Detection in Screening // HPV Today. 2006. — Vol. 8. — P.8−9.
- Solomon D., Davey D., Kurman R., et al, for the Forum Group Members and the Bethesda 2001 Workshop. The 2001 Bethesda System: Terminology for reporting results of cervical cytology // JAMA. 2002. — Vol. 287. — P. 21 142 119.
- Spiryda L.B., Brown M., Ke Creek, Pirisi Creek L. Risk factors for CIN 2/3 in HGSIL cases // Abstract. 25th International Papillomavirus Conference. Malmo, Sweden, 2009. — P -03.42.
- Spitzer M. Screening and management of women and girls with human papillomavirus infection // Gynecol. Oncol. -2007. -107 (2 Suppl.):S14−8. Links.
- Stoler M.H. Human papillomavirus biology and cervical neoplasia: implications for diagnostic criteria and testing // Arch. Pathol. Lab. Med. 2003. -Vol. 127. — P. 935−939.
- Stuart G., Taylor G., Bancej C.M., et al.: Report of the 2003 pan-Canadian forum on cervical cancer prevention and control // J. Obstet. Gynaecol. Can. -2004. Vol. 26. — № 11. — P. 1004−1028.
- Taylor S., Kuhn L., Dupree W., et al. Direct comparison of liquid-based and conventional cytology in a South African screening trial // Int. J. Cancer. -2006. Vol. 118. — № 4. — P. 957−962.
- Tench W. Preliminary assessment of the AutoCyte PREP: direct-to-vial performance // J. Reprod. Med. 2000. — Vol. 45. — P. 912−916.
- The American Cancer Society. Facts and Figures 2005. http://www.cancer.org/.
- The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance // Am. J. Obstet. Gynecol. 2003. — Vol. 188. — № 6.-P. 1383−1392.
- Tidy J. Forgotten implications of HPV positivity for the majority of females: a clinical perspective // Cytopathology. 2002. — Vol. 13. — № 5. — P. 263−266.
- Trottier H., Mahmud S.M., Lindsay L., et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women // Cancer Epidemiol. Biomarkers Prev. 2009. — Vol. 18. -№ 3. — P. 854−862.
- Trottier H., Ferreira S., Prado J.C.M., et al. HPV in older woman is associatedjL 4 #with new sexual partners // The 25 international papillomavirus conference. -Malmo, Sweden, 2009. 0−06.02.
- Vaccarella S., Herrero R., Dai M., et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys // Cancer Epidemoil. Biomarkers Prev. 2006. — Vol. 15.-№H. p. 2148−2153.
- Vaccarella S., Franceschi S., Herrero R, et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys // Cancer Epidemiol. Biomarkers Prev. 2006. — Vol. 15 -№ 2.-P. 326−333.
- Waggoner S. Cervical cancer // Lancet. 2003. — Vol. 361. — № 9376. — P. 2217−2225.
- Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide // J. Pathology. 1999. -Vol. 189. -№ 1. -P.12−19.
- Walker P., Dexeus S., De Palo G., et al. International terminology of colposcopy: an updated report from the International Federation for Pathology and Colposcopy // Obstet. Gynecol. 2003. — Vol. 101. — P. 175−177.
- Wallin K.L., Wiklund F., Angstrom T., et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer//N. Engl. J. Med. 1999. — Vol. 341. — P. 1633−1638.
- Weintraub J., Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer // Diagn. Cytopathol. 2000. — Vol. 22. — № 1. — P. 52−59.
- WHO. Sixth report on the world health situation. Part I. Global analyses. -Geneva, 1968.
- Winer R.L., Lee S.K., Hughes J.P., et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students // Am. J. Epidemiol. 2003. — Vol. 157. — № 3. — P. 218−226.
- Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women // N. Engl. J. Med. 2006. Vol. 354. — P. 2645−2654.
- World Health Organization (WHO). Comprehensive Cervical Cancer Control. A guide to essential practice. Geneva: WHO 2006. http ://www. who. int/reproductivehealth/publications/cervicalcancergep/ text.pdf.
- Wright T.C. Cervical cancer screening using visualization techniques // J. Natl. Cancer Inst.-2003. Vol. 31. — P. 66−71.
- Wright T.C. Jr., Schiffinan M. Adding a test for Human papillomavirus DNA to cervical cancer screening // N. Engl. J. Med. 2003. — Vol. 348. — № 6. — P. 489−490.
- Wright T.C. Jr., Schiffinan M., Solomon D., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening // Obstet. Gynecol. 2004. — Vol. 103. — P. 304−309.
- Wright T.C. Jr., Denny L., Kuhn L. Novel screening strategies that could reduce the role of cytology in cervical cancer screening programs. 2006. Submitted for publication.
- Wright T.C. Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? // Clin. Obstet. Gynecol. 2007. — Vol. 50. — № 2. — P. 313−323.
- Wu D., Ding L., Wu J.H., Li Z.N. Application of liquid-based cytology and high-risk human papillomavirus DNA detection in cervical lesion screening // Cancer. -2007. Vol. 27. — № 9. — P. 1421−1423.
- Zhao F.H., Hu S.Y., Wang S.M., et al. Association between high-risk human papillomavirus DNA load and different histological grades of cervical neoplasia. [Article in Chinese] // Zhonghua Yu Fang Yi Xue Za Zhi. 2009. — Vol. 43.-№ 7.-P. 565−570.
- Zur Hausen H. Disrupted dichotomous intracellular control of Human papillomavirus infection in cancer of the cervix // J. Cancer. 1994. — Vol. 343. — P. 955- 957.